Please login to the form below

Not currently logged in
Email:
Password:

Nycomed strengthen CEE presence

Swiss company buys 20 branded generics from sanofi-aventis and Zentiva

Nycomed has agreed to buy 20 branded generic products from sanofi-aventis and Zentiva in an attempt to strengthen its market position in Central and Eastern Europe, in particular in the Czech Republic and Slovakia.

Under the terms of the deal, Nycomed will acquire a portfolio of branded generic drugs in the Czech Republic, Slovakia, Romania, Hungary, Estonia and Bulgaria, with an annual turnover of around €17m. In addition, Nycomed will also assume future production.

As part of the deal, Nycomed has purchased Zentiva's well-established hypnotic hypnogen (zolipidem) in the Czech Republic, Slovak Republic and Estonia.

Most of the purchased products are in the Czech Republic and include a strong franchise of beta-blockers (Vasocardin, Betaxa and Tenoloc), which will bolster the company's cardiovascular business around Ebrantil. Other brands include Trental, Flavobion and Ercefuryl.

"These brands will complement our local portfolios very well," said Frank Rotmann, area manager Central and Eastern Europe, Nycomed.

The purchase will be completed as an asset transfer transaction – no further financial details of the deal were available. The European Commission and the Czech Antimonopoly Office have approved the deal, which is expected to close in September 2009. 

3rd August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics